目的 观察醒脑静注射液联合阿托伐他汀治疗急性脑出血的临床疗效。方法 选取2013年1月-2014年12月延安大学咸阳医院收治的急性脑出血患者120例,随机分为对照组和治疗组,每组各60例。对照组患者在常规治疗的基础上口服阿托伐他汀钙片,20 mg/次,1次/d。治疗组患者在对照组的治疗基础上静脉滴注醒脑静注射液,20 mL/次,以生理盐水500 mL稀释后滴注,2次/d。两组均连续治疗12周。观察两组的临床疗效,比较两组治疗过程中C反应蛋白(CRP)、白细胞介素1β(IL-1β)、肿瘤坏死因子α(TNF-α)、一氧化氮(NO)、丙二醛(MDA)、超氧化物歧化酶(SOD)活性以及神经功能缺损(NIHSS)评分的变化情况。结果 治疗后,对照组和治疗组的总有效率分别为73.33%、88.33%,两组比较差异有统计学意义(P < 0.05)。治疗后,两组CRP、IL-1β、TNF-α、MDA、NO、NIHSS评分均显著降低,SOD显著升高,同组治疗前后差异具有统计学意义(P < 0.05);且治疗组这些观察指标的改善程度优于对照组,两组比较差异具有统计学意义(P < 0.05)。结论 醒脑静注射液联合阿托伐他汀治疗急性脑出血具有较好的临床疗效,可降低炎症相关因子和NIHSS评分,具有一定的临床推广应用价值。

Objective To observe the clinical efficacy of Xingnaojing Injection combined with atorvastatin in treatment of acute cerebral hemorrhage. Methods Patients (120 cases) with acute cerebral hemorrhage in Xianyang Hospital of Yan'an University from January 2013 to December 2014 were randomly divided into control and treatment groups, and each group had 60 cases. The patients in the control group were po administered with Atorvastatin Calcium Tablets on the basis of conventional treatment, 20 mg/time, once daily. The patients in the control group were iv administered with Xingnaojing Injection, 20 mL/time, which was added into normal saline 500 mL, twice daily. Two groups were treated for 12 weeks. After treatment, the efficacy was evaluated, and the changes of CRP, IL-1β, TNF-α, NO, MDA, SOD, and NIHSS scores in two groups were compared. Results After treatment, the efficacies in the control and treatment groups were 73.33% and 88.33%, respectively, and there were differences between two groups (P < 0.05). After treatment, CRP, IL-1β, TNF-α, MDA, NO, and NIHSS scores were significantly decreased, and SOD was significantly increased, and the difference was statistically significant in the same group (P < 0.05). These observational indexes in the treatment group were better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Xingnaojing Injection combined with atorvastatin has good clinical curative effect in treatment of acute cerebral hemorrhage, and can reduce the inflammation related factors and NIHSS scores, which has a certain clinical application value.